Trisenox® in Women With Metastatic Endometrial Cancer

Phase 2

Terminated

Conditions: Endometrial Carcinoma

Interventions: Drug: Arsenic trioxide

Registration Number: NCT01184053

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Brief Summary: The primary purpose of this study is to see whether women who have already received chemotherapy for their endometrial cancer, or who have disease that has spread outside of the uterus, will respond to the drug arsenic trioxide (Trisenox®) as judged by shrinkage of their tumor.

Detailed Description: This is an open-label, single arm, single institution, phase II trial designed to assess the response rate and safety of Trisenox® in women with recurrent endometrial carcinoma. Trisenox® will be administered at a dose of 0.25 mg/kg/day for 5 consecutive days (D1-5) every 4 weeks. A 4-week period will be defined as a cycle of treatment. Marker and non-marker lesions will be assessed every 2 cycles (every 8 weeks) and the response assigned according to Gynecologic Oncology Group (GOG) RECIST guidelines. Safety will be assessed by routine physical, laboratory and ECG evaluations. Up to 10 patients will be enrolled into the study. Patients are expected (excluding any unforeseen toxicities) to receive a minimum of 2 and a maximum of 6 cycles of Trisenox®. (Patients with at least documented stable disease may be eligible for \>6 cycles). Patients will be followed for 6 months after their last dose of Trisenox®.

For this trial we would allow one prior cytotoxic regimen since the time of recurrence and patients may have had one prior regimen as part of their induction chemotherapy. Patients will be treated with 0.25 mg/kg/day for days 1-5 every 28 days and patients may remain on trial until progression of disease.

Recruitment & Eligibility

Status: TERMINATED

Sex: Female

Target Recruitment: 3

Inclusion Criteria

≥18 years of age with histologically confirmed metastatic or recurrent endometrial cancer
Documented progression of their endometrial cancer (i.e., within the last 3 months)
If of childbearing potential they must agree to use approved barrier methods of contraception
Presence of at least one measurable lesion that:
- Can be accurately measured in at least one dimension with longest diameter ≥20 mm using conventional techniques or ≥10 mm with spiral CT scan (or otherwise at least twice the reconstruction interval for CT or MRI scans).
- Previously irradiated lesions may be considered to be measurable provided: 1) there has been documented progression of the lesion(s) since completion of radiotherapy, and 2) the criteria for measurability as outlined above are met.
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Minimum life expectancy of 3 months
Adequate renal and hepatic function (per study protocol guidelines)
Adequate bone marrow function (per study protocol guidelines)
Serum cholesterol <350 mg/dL and triglycerides < 400 mg/dL
Able to understand and give written informed consent
Ejection fraction >55% with no focal left ventricular wall motion abnormalities in patients with a history of coronary artery disease or a history of congestive heart failure.

Exclusion Criteria

Women who are pregnant or lactating
Presence of brain metastases
Two or more prior cycles of cytotoxic chemotherapy since recurrence (Two total regimens are allowed if one includes adjuvant therapy.)
Prior therapy with Trisenox or known sensitivity to this agent
Prior anticancer treatment (chemotherapy, radiotherapy, immunotherapy, biological response modifiers, signal transduction inhibitors, etc) within 4 weeks prior to the first dose of Trisenox.
Ongoing toxicity associated with prior anticancer therapy (except peripheral neuropathy of ≤ grade 1 by NCI toxicity criteria)
Another primary malignancy within the past three years (except for non-melanoma skin cancer and cervical carcinoma in situ)
Significant uncontrolled cardiovascular disease
Active infection requiring systemic therapy
Known HIV infection
Treatment with any investigational agent within 4 weeks prior to the first dose of Trisenox
Concurrent treatment with immunosuppressive agents other than prescribed corticosteroids
Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to the first dose of Trisenox
Patients having undergone recent placement of a central venous access port will be considered eligible if they have recovered
Presence of any other life-threatening illness or organ system dysfunction which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluating the safety of the study drug
Prolonged absolute corrected QT interval (QTc) interval > 500 msec
Underlying conduction disease that prevents measurement of QT interval
History of ventricular tachycardia or any cardiac arrhythmia requiring the placement of an automated intraventricular cardiac defibrillator.
Inability to discontinue therapy with class I or class III antiarrhythmic medications.
Inability to discontinue drugs known to be associated with a risk for torsades de pointes

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Trisenox treatment	Arsenic trioxide	Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.

Primary Outcome Measures

Name	Time	Method
Objective Response (CR+PR) Rate of Subjects Given Trisenox	28 days	To estimate the objective response (CR+PR) rate (as defined by the Gynecologic Oncology Group \[GOG\] RECIST Criteria)of Trisenox® in women with recurrent or metastatic endometrial cancer when administered at 0.25 mg/kg/day for 5 consecutive days (D1-5) every 4 weeks.

Secondary Outcome Measures

Name	Time	Method
Overall Survival	5 years
Associations Between Markers of Angiogenesis (e.g. VEGF) With Response	4 years	We will request a blood sample to measure vascular endothelial growth factor (VEGF) as well as other angiogenic factors and correlate levels to response to arsenic trioxide. Such effects have been observed in cultured cell lines and animal models, as well as clinical studies.
Progression Free Survival in Patients Treated With Trisenox®	28 days	Progression-Free survival is the period from start of treatment until disease progression, death, or date of last contact.